CAMP4 appoints Michael MacLean to Board, effective April 1, 2026

Camp4 Therapeutics Corp

Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.
MacLean appointed to Audit and Compensation Committees; will receive standard director compensation.
Board amended non-employee director compensation policy: new directors granted options for 56,000 shares vesting over 3 years.
MacLean brings over 35 years of financial leadership in biotech, including roles at Avidity, Akcea, PureTech, and Biogen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.